Prognosis of the individual course of disease: the elements of time, heterogeneity and precision
- PMID: 20106349
- DOI: 10.1016/S0022-510X(09)71301-2
Prognosis of the individual course of disease: the elements of time, heterogeneity and precision
Abstract
There is no gold standard in monitoring disease activity for clinical trials in multiple sclerosis. Various outcome measures, including relapses, disability and magnetic resonance imaging (MRI) measures have been used to demonstrate the efficacy of the different available therapies for multiple sclerosis. Recently, the potential limitations of these measures have received increasing attention, and these have stimulated research into more appropriate and sensitive outcome measures for clinical trials. For example, it has been shown that widely-used MRI measures add little, if any, independent information to that provided by more clinically relevant measures such as relapses and disability. Similarly, the Expanded Disability status Scale (EDSS), which is the most widely-used measure of disability related to multiple sclerosis, is insufficiently sensitive to detect robust changes in disability over the timeframes usually used in clinical trials. An alternative to the EDSS is the Multiple Sclerosis Severity Score (MSSS), a severity scale which relates clinical disability to disease duration. The MSSS was originally developed from a database of nearly ten thousand patients from eleven European countries and Australia and has since been reproduced in an independent dataset of 1134 patients from the placebo arms of randomised clinical trials. Based on the MSSS score, disease severity can be defined, which shows stability over time and may provide evidence-based decision support for patient management. Another alternative to measure disability is the objective quantification of physical activity. There is evidence that recent developments in pervasive computing using tiny accelerometers may have the potential to increase the reliability and precision of motor assessment, especially in the mid-range of the EDSS. The outcome measures discussed have potential use as online tools for evidence-based decision support which are increasingly being used in medical research and clinical decision-making.
Copyright 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
MRI as an outcome in multiple sclerosis clinical trials.Neurology. 2009 Feb 24;72(8):705-11. doi: 10.1212/01.wnl.0000336916.38629.43. Epub 2008 Dec 10. Neurology. 2009. PMID: 19073945
-
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8. Neurology. 2005. PMID: 15824338
-
Assessing disability progression with the Multiple Sclerosis Functional Composite.Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212. Mult Scler. 2009. PMID: 19667023
-
Management of worsening multiple sclerosis with mitoxantrone: a review.Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
-
Clinical outcome measures in multiple sclerosis.J Neurol Sci. 2007 Aug 15;259(1-2):118-22. doi: 10.1016/j.jns.2006.06.031. Epub 2007 Mar 21. J Neurol Sci. 2007. PMID: 17376487 Review.
Cited by
-
Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.BMC Neurol. 2016 Aug 8;16:129. doi: 10.1186/s12883-016-0648-6. BMC Neurol. 2016. PMID: 27502119 Free PMC article. Clinical Trial.
-
Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort.Neurol Sci. 2025 Jan;46(1):335-342. doi: 10.1007/s10072-024-07767-3. Epub 2024 Sep 17. Neurol Sci. 2025. PMID: 39285108 Free PMC article.
-
Regarding the publication The Multiple Sclerosis Severity Score: Fluctuations and prognostic ability in a longitudinal cohort of patients with MS authored by RH Gross et al.Mult Scler J Exp Transl Clin. 2020 May 22;6(2):2055217320927421. doi: 10.1177/2055217320927421. eCollection 2020 Apr-Jun. Mult Scler J Exp Transl Clin. 2020. PMID: 32547777 Free PMC article. No abstract available.
-
Genome-wide association study of severity in multiple sclerosis.Genes Immun. 2011 Dec;12(8):615-25. doi: 10.1038/gene.2011.34. Epub 2011 Jun 9. Genes Immun. 2011. PMID: 21654844 Free PMC article.
-
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.Mult Scler. 2017 Jun;23(7):956-962. doi: 10.1177/1352458516669441. Epub 2016 Sep 12. Mult Scler. 2017. PMID: 27620894 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical